Fibrotic ILDs in autoimmune rheumatic diseases: how have the treatment guidelines and treatment options evolved?
Chair: Prof Ho So
Autoimmune rheumatic diseases can lead to severe internal organ complications leading to significant mortality through impact on respiratory or cardiac function. This includes development of interstitial lung disease (ILD). The pattern and frequency of ILD differs between autoimmune rheumatic diseases. Systemic sclerosis has the highest frequency of ILD and provides a template for the assessment and management. Recent studies have defined the patterns of disease and started to identify risk factors for progressive or severe ILD. These findings can be incorporated into clinical practice, and this allows treatments, including emerging anti-fibrotic therapy to be incorporated into clinical practice. There are now expert guidelines covering the assessment and treatment of ILD in systemic sclerosis. In addition, recent trials, such as the INBUILD trial of nintedanib, and expert recommendations for assessment of ILD, have defined progressive lung fibrosis as an important group of patients with high unmet need that may arise in the context of several different autoimmune rheumatic diseases including rheumatoid arthritis, mixed connective tissue disease and inflammatory myopathy. This presentation will summarise current approaches to fibrotic ILD in autoimmune rheumatic disease, review evidence-based treatment options and signpost relevant treatment guidelines.
Fibrotic ILDs in autoimmune rheumatic diseases: how has the treatment guidelines and treatment options evolved?
Prof Christopher Denton
Review on ILDs: Diagnosis and risk factors
Rheumatologist perspectives – Screening, symptoms assessment and risk factors
Prof Anna Hoffman-Vold
Pulmonary perspectives – importance of lung function test and co management
Prof Michael Kreuter
Radiologist perspectives – HRCT and differential diagnosis
Prof Joseph Jacob